StocksMedium•27 October 2026•
1 min read
Aclaris Therapeutics Reports Positive Phase 1b Results for ATI-052 in Asthma and Dermatitis
Key Facts
1Aclaris Therapeutics announced positive Phase 1b proof-of-concept primary analysis results for its bispecific ATI-052 in atopic dermatitis and asthma.
Aclaris Therapeutics announced positive Phase 1b proof-of-concept primary analysis results for its bispecific ATI-052 in atopic dermatitis and asthma. GlobeNewswire reported that the drug, which targets inflammatory conditions by inhibiting TSLP and IL-4Rα, met its primary objectives in the clinical evaluation.
ACRS closed at $3.79 on October 26, 2026, prior to the release of the trial data. During the October 26, 2026 session, the stock reached a high of $3.85 and a low of $3.72 as the company continues to advance its clinical pipeline for ATI-052.